Potential negative impact of reputed regulators’ decisions on the approval status of new cancer drugs in Latin American countries: A descriptive analysis

BACKGROUND: Many new cancer drugs are being approved by reputed regulatory authorities without evidence of overall survival benefit, quality of life improvement, and often based on clinical trials at high risk of bias. In recent years, most Latin American (LA) countries have reformed their marketing...

Descripción completa

Detalles Bibliográficos
Autores principales: Durán, Carlos E., Cañás, Martín, Urtasun, Martín, Elseviers, Monique, Vander Stichele, Robert, Christiaens, Thierry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8277058/
https://www.ncbi.nlm.nih.gov/pubmed/34255795
http://dx.doi.org/10.1371/journal.pone.0254585

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8277058/
https://www.ncbi.nlm.nih.gov/pubmed/34255795
http://dx.doi.org/10.1371/journal.pone.0254585

Ejemplares similares